Drug intelligence / Profile preview

LOAd713

Development stage: Preclinical
Lead developer: Uppsala University
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

LOAd713 is an oncolytic adenovirus designed to block IL-6R signaling and provide myeloid cell activation via a trimerized membrane-bound isoleucine zipper (TMZ) CD40L. It is primarily aimed at treating cancers connected to IL-6 signaling, such as pancreatic cancer. LOAd713 can kill infected tumor cells and modulate the tumor microenvironment by reducing factors involved in stroma formation and promoting immune responses.

Targets

IL-6R (Interleukin-6 receptor subunit alpha)CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on LOAd713.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LOAd713.

Explore the full profile